Global Stem Cells Group Signs Prominent Plastic Surgeon Alfred Hoyos, M.D., Creator of High Definition Liposculpture
MIAMI (PRWEB) October 13, 2014 -- Global Stem Cells Group, Inc. has signed Stemlab.com founder and prominent plastic surgeon Alfredo Hoyos, M.D. to represent the Miami-based stem cell company as an exclusive representative for the Colombian territory. Hoyos is the world-renowned creator of high-definition liposculpture and other advanced body contour techniques.
Hoyos will join Kristin Comella, Chief Scientific Officer of BioHeart, Inc., to combine his Stemlab medical team with her regenerative medicine protocols to promote research and cutting-edge stem cell technology in Colombia. In addition, Hoyos and Comella will team up in 2005 to provide five stem cell training sessions to medical professionals in Colombia, and establish the country’s first symposium on stem cell therapies and regenerative medicine.
Global Stem Cells Group searches the globe for innovative stem cell practitioners that fit in with the Colombian markets. Hoyos will be in charge of all Global Stem Cells Group divisions and programs in Colombia, including patient recruiting through Regenestem, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket.
Regenestem, Stem Cell Training and Adimarket are regenerative medicine companies under the Global Stem Cells Group brand.
“Our main objective is to organize Colombia’s first symposium on stem cells and regenerative medicine in 2015,” says Global Stem Cells Group Founder Benito Novas. “Our new alliance with Dr. Hoyos and StemLab.com will allow us to establish our brand as the leader in regenerative medicine therapies in Colombia.”
Global Stem Cells Group’s strategy is to expand into foreign markets by recruiting local representatives and distributors like Hoyos to help manage the company’s growth in a specific geographic area. Global Stem Cells group requires any company under consideration for the expansion program to have more than five years experience in the health care industry with at least some experience in the field of regenerative medicine .
In addition, geographic alliances require a commitment to a number of stem cell training courses during a one-year period, certification of physicians, and willingness to organize a large medical meeting or symposium in their territory.
To learn more about the Global Stem Cells Group alliance program, vitis the website at http://www.stemcellsgroup.com, email bnovas(at)stemcellsgroup(dot)com, or call 305.224.1858.
About Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About Alfredo Hoyos, M.D.:
Colombia-based plastic surgeon Alfredo Hoyos, M.D. takes advantage of his talent as a painter and sculptor to perform high-definition liposculpture, giving his patients athletic-looking bodies with minimal scarring. The creator of high-definition liposculpture and other advanced body contour techniques, Hoyos combines his expertise in regenerative medicine therapies with other technologies to achieve spectacular results in aesthetic and anti-aging medicine.
Hoyos is the founder of Stemlab, a biotechnology company committed to developing new techniques using (stromal) stem cells derived from adipose tissue to improve the quality of life for people.
About BioHeart, Inc.:
Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.
Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.
About Stemlab:
Stemlab is an innovative biotechnology company that aims to fill gaps in the processing and handling of stem cells derived from stromal adipose tissue using the latest technologies in regenerative medicine. The goal is to expand the therapeutic arsenal to increase the options in the treatment of chronic diseases and improve every patient’s quality of life.
###
Benito Novas, Global Stem Cells Group, http://www.globalstemcellsgroup.com, +1 (813) 965-4373, [email protected]
Share this article